Renal involvement in diffuse large B-cell lymphoma: A case report

Kaynakça (3)

1. Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Biomed Study Group. Ann Oncol 1997;8 Suppl 2:49-54
2. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004;124:151-9
3. Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012;118:4166-72. doi:10.1002/ cncr.27381 [4] Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011;96:1002-7. doi:10.3324/ haematol.2011.041277 [5] Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. doi:10.1200/JCO.2005.07.155 [6] Lehners N, Kramer I, Schwarzbich MA, Ho AD, Witzens- Harig M. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk7869 [7] Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol 2011;90:809-18. doi:10.1007/s00277.010.1150-7 [8] Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 2014;55:2228-40. doi:10.3109/10428.194.2013.86 9326 [9] Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046-52. doi:10.1093/annonc/mdp432 [10] Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012;23:1267-73. doi:10.1093/annonc/ mdr440 [11] Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituxim